A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Diagnosis of tumor is one of the most important stages in the treatment, as good quality imaging and accurate analysis means to choose the right and more effective tracer. Therefore, the study of the ability of new radiopharmaceutical compound to track solid tumor became a pioneering field. Thus, the study of pipazethate as a possible solid tumor marker was in our scope. It was labeled with technetium reaching a (RCY) radiochemical yield of 96.5%, using SnCl2 .2H2O as a reducing agent. Adoi:10.21608/ajnsa.2022.115910.1544 fatcat:kcy6p5mhqzeqdnjsg7kc243dcm